Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Gilead Sciences (GILD) Tops Q4 EPS by 9c, Offers FY17 Guidance
February 9, 2017 6:41 AM EST
BMO Capital Markets analyst M. Ian Somaiya maintains Market Perform rating, but drops price target on Gild Sciences (NASDAQ: GILD) to $75 (from $88), as the company delivered guidance well below consensus, forcing the Street to cut estimates.
Somaiya comments, "We are maintaining our Market... More
February 8, 2017 11:09 AM EST
Following its 'kitchen sink' HCV guidance and subsequent 9% sell-off, the urgency for Gilead Sciences (NASDAQ: GILD) to make an acquisition continues to intensify. On the call, the company essentially admitted that it cannot grow over the next few years without a... More
February 8, 2017 9:40 AM EST
Gilead Sciences (NASDAQ: GILD) Pressured on Market Open, Shares Down 10%
...
More
February 8, 2017 6:57 AM EST
Needham & Company reiterated a Hold rating on Gilead Sciences (NASDAQ: GILD) following the company's 4Q earnings report.
Analyst Alan Carr commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by... More
February 8, 2017 6:19 AM EST
Baird analyst Brian Skorney maintains Outperform rating, but lowers price target on Gilead Sciences (NASDAQ: GILD) to $87 (from $100), as the company provided fiscal year revenue guidance well below consensus.
Skorney notes, 2017 guidance likely to bottom out stock. We believe investors were expecting... More
